HistoSonics has filed a notice of an exempt offering of securities to raise $102,000,001.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, HistoSonics is raising up to $102,000,001.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Mike Blue played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About HistoSonics
HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The companys new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of todays interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.
To learn more about HistoSonics, visit http://www.histosonics.com/
HistoSonics Linkedin Page: https://www.linkedin.com/company/histosonics-inc-/
Contact:
Mike Blue, President and Chief Executive Officer
877-740-0543
https://www.linkedin.com/in/mike-blue-860b9522/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.